Latest News

  • Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder Read More
  • Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference Read More
  • Alkermes Media Statement Regarding FDA Warning Letter Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team